Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
Is the best strategy against omicron to keep boosting with the original vaccine?
Federal health officials are urging all vaccinated adults to get their Covid booster shot amid growing alarm over the...
-
‘Part of a new normal:’ Covid reinfections are here to stay
In 2020, Covid reinfections were considered rare. In 2021, breakthrough infections in vaccinated individuals could occur, but again, the...
-
U.K.’s first non-white leader? Finance minister Sunak wins praise for staying calm in a crisis
LONDON — It’s been a tough year for front-line politicians in Britain. Few have impressed as the country battles...
-
Blue dragon season is upon us, but researchers remind beachgoers to think twice before touching them
CORPUS CHRISTI, Texas — Spring breakers flocking to Texas beaches this month could stumble upon a sight many have...
-
J&J vaccine remains on pause as CDC panel requests more information
An advisory panel to the Centers for Disease Control and Prevention declined to make any new recommendations on the...
-
10 doctors on FDA panel for Abbott heart device had financial ties to the company
When the Food and Drug Administration recently convened a committee of advisers to assess a cardiac device made by...
-
Some worry that the first FDA-approved at-home test for STIs could make things worse
The Food and Drug Administration’s first-ever approval of an at-home test for chlamydia and gonorrhea could help drive earlier...
-
Nearly 1 million pediatric Covid cases reported last week
Nearly 1 million cases of Covid-19 were reported among children in the United States last week, the American Academy...
Recent Comments